Clinical Trial Update: T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating T-DM1 with non-pegylated liposomal doxorubicin in HER2-positive metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Non-pegylated liposomal doxorubicin (doxorubicin liposome)
• T-DM1 (ado-trastuzumab emtansine)

Snippet

Sponsor: MedSIR | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2022-01-18